Partnership will use Carna’s proprietary lipid kinase drug discovery platform, bringing another aspect to Gilead’s IO efforts. Catalent continues expansion by acquiring Novavax R&D assets; Genfit licenses elafibranor in China to Terns.

Novartis and Gilead longer-term data show largely steady response and survival rates, shoring up the clinical and commercial case for their products and justifying continued investment in T-cell therapies. The CAR-T pioneers discuss their progress, including with allogeneic platforms, with Scrip at ASH.

While Milligan’s year-end departure topped the news, Gilead posted solid sales growth for Yescarta, got the HIV franchise back to growth and saw HCV’s decline largely stabilize. CSO McHutchison, meanwhile, predicted that selonsertib could be first to market in NASH.

Deal through Kite Pharma subsidiary focuses on developing gamma delta T-cell receptor therapies. Sanofi inks SHP2 cancer collaboration with Revolution, while Vical considers its strategic options.